Clinical Trial Update: Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated whether early versus delayed administration of everolimus improves outcomes and safety in de novo kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Zortress (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2011-01-26